Drug Development Pipeline
RELiZORB® is a digestive enzyme cartridge that connects to enteral tube feeding systems. It is designed to mimic normal pancreatic function by helping to break down the fats in enteral tube feeding formula. By breaking down these fats before the formula is ingested, RELiZORB® may allow for delivery of increased absorbable calories and simplify the use of enzymes in overnight feedings.
RELiZORB® is FDA-approved for people who are partially or completely unable to break down and absorb fats. Two studies to test the safety, tolerability and effectiveness of RELiZORB® in people with CF have been completed.
This program was sponsored by Alcresta and partially funded by the Cystic Fibrosis Foundation. It was conducted within the Therapeutics Development Network.
In July 2017, The U.S. Food and Drug Administration (FDA) approved the use of RELiZORB® for children ages 5 to 18 who use a feeding tube. The FDA initially approved use of the enzyme cartridge for tube feeding for people ages 18 and over.
Sign up for clinical trial alerts
Get email updates about clinical trials that matter to you.
Explore clinical trials
Be a part of the movement transforming the future of cystic fibrosis treatment.Learn More